Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (December 2019)
31 slides from Bioxytran's investor presentation, Dec 11, 2019
Slide 1: Se \. ha \
% Se \. ha \ david.pla acoder q err 510 539 Wh x y,
Slide 2: Mission Statement
Mission Statement BioxyTran’s mission is to develop effective drug treatments for hypoxia (oxygen deficiency) which delivers oxygen to tissues with the potential to improve a myriad of medical conditions BioXyTran..
Slide 3: Definition of Hypoxia
Definition of Hypoxia ® hy-pox-i-a /hi paksée/ noun MEDICINE deficiency in the amount of oxygen reaching the tissues. + oxygen deficiency in a biotic environment. “aquatic hypoxia’ Bio.XyTran..
Slide 4: How Important is Oxygen?
How Important is Oxygen? How long can you hold your breath? Average Healthy Person can hold their breath about 2 minutes. Free Divers can hold their breath 3 — 5 minutes but can go down 100 meters BioXyTran.. iy sel
Slide 5: Survival Pyramid
Survival Pyramid What We Can’t Live Without 4-6 Minutes without oxygen 3 Days without water 21 Days without food Bio.XyTran..
Slide 6: Hypoxia Implicated in Many Medical Conditions
Hypoxia Implicated in Many Medical Conditions ¢ AGING?COPD: = CANC ER PNEUMONIA Y Cystic Fibrosis ua wm PSORIASIS £ 8Roncuitis © PULMONARY EDEMA Y > = STROKE joiasetes - Pheumatoid Arthritis ECZEMA 2 = Crohn's Disease £ ULCERATIVE COLITIS = “NSESTNENEART = LIVER FIBROSIS AND CIRRHOSIS |“ LLJ HEART A
Slide 7: Cure for Hypoxia = OXYGEN
Cure for Hypoxia = OXYGEN Hypoxia N https://www.nobelprize.org/prizes/medicine/2019/press-release/ Nobel Prize Laureates Bio,.XyTran..
Slide 8: Hypoxia Science Research Won the Nobel Prize in 2019
FE 4 z 3 a > rd a Hypoxia Science Research Won the Nobel Prize in 2019 2019 NOBEL PRIZE WINNERS William Kaelin Jr, Sir Peter Ratcliffe, and Gregg Semenza Discovery: how cells adapt to changing oxygen levels Bio.XyT ran. ~~ ya BIOXYTRAN... World Leader in the Field of Hypoxia QO) BioxyTran has the on
Slide 9: BioxyTran Is Developing an Oxygen Transport Molecule - BXT-25
BioXyTran.. BioxyTran Is Developing an Oxygen Transport Molecule — T-25 y Universal Challenge: Delivering oxygen to ischemic tissues and measuring the effect of increased oxygen levels Heme Hemoglobin Erythrocyte Solution: Separating HEME from GLOBIN - Create molecule 5,000 times smaller than a red
Slide 10: Expected Safety Profile of the Drug BXT-25
Bio.XyTran.. Expected Safety Profile of the Drug BXT-25 ye BioxyTran Combines Heme with a Co-Polymer Heme: An FDA approved material Co-polymer - FDA Approved Sugar that identifies and delivers oxygen + Stabilized Heme in Blood that eliminates similar to red blood cells Nitric Oxide Scavenging https:
Slide 11: FDA Approved MDX Viewer Measures Hypoxia
Bio XyTran.. FDA Approved MDX Viewer Measures Hypoxia — Tool for Facilitating Drug Approval Approved Device Status Facilitates Defining Endpoint Flat probe (B) Anterior cerebral artery Treated Aneurysm Posterior cerebral artery Middle cerebral artery Potential Endpoints U Tissue Metabolic Score FDA
Slide 12: Elements of a Blockbuster Drug
Bio.XyTran.. Elements of a Blockbuster Drug -Generate over $1.0 billion in annual revenue Blockbuster Drug List Lipitor, Epogen, Viagra, Taxol Keytruda, Revlimid, Humira BXT-25? -Treat chronic diseases spanning many years -Nominal side effects -Platform technology -Strong Intellectual property posit
Slide 13: Bioxytran Following Celgene's Example
Bioxytran Following Celgene’s Example Celgene repurposed thalidomide which created a $74 billion purchase by Bristol Myers Squibb in 2019 -First approval in 1957 as a sedative — sleeping pill -Few year later marketed as anti-nausea/morning sickness drug -Pulled from market after 10K cases of birth d
Slide 14: Bioxytran May Create Significant Value by Upgrading Hemopure with New Chemistry
Bioxytran May Create Significant Value by Upgrading Hemopure with New Chemistry South Africa: 2001 Russia: 2012 United States: Veterinary use only Hemopure Regulatory Approval History: Expanded Access approval in the U.S.: for qualifying patients with severe, life threatening anemia for whom blood t
Slide 15: Hemopure Research Supports Bioxytran's Value
Bio.XyTran... i sl v Hemopure Research Supports Bioxytran’s Value BXT-25 will be designed to; ¢ Deliver optimum oxygen type to tissues ¢ Increase measurable oxygen tissue levels ¢ Restore organ functionality ¢ Mitigate Hemopure’s side effects (nitric oxygen scavenging)
Slide 16: BXT-25 Will Optimize the Efficacy of Prior Technology
BXT-25 Will Optimize the Efficacy of Prior Technology BioXyTran.. a @ 100 Years Research @ $460MM in R&D @ 400 Peer Reviewed Articles @ 27 Clinical Trials @ 830 Patients Dosed @ 2 Animal Studies @ 510(K) Approval @ Approved in South Africa, Russia & U.S. (Veterinary) @ Carbohydrate Binding Heavy Met
Slide 17: Strategy for Successful Commercialization of BXT-25
Strategy for Successful Commercialization of BXT-25 Pursue functional claim of tissue oxygenation Finalize development of MDX Viewer Prioritize stroke application in near term Explore a myriad of other applications/treatments Build core team to scale future growth Enhance IP value through licensing
Slide 18: BioxyTran Will Pursue a Functional vs. a Medical Claim
Bio.XyTran.. BioxyTran Will Pursue a Functional vs. a Medical Claim ~N- Most Drug Development Companies Pursue Medical Claims Example: Medical Claim (disease): The applicant claims the drug is for the treatment of ischemic stroke. The clinical endpoint for stroke is based on subjective cognitive tes
Slide 19: Big Pharma Licensing Targets for BXT-25
Big Pharma Licensing Targets for BXT-25 BioXyTran:. Oncology Respiratory Neuroscience Hematology Immunology Inflammation Cardiovascular Stroke Oncology Neuroscience Immunology Cardiovascular Oncology Neuroscience Immunology Hematology Oncology Neuroscience Cardiovascular ) _ Oncology Neuroscience Im
Slide 20: Licensing Represents A Significant Opportunity
Licensing Represents A Significant Opportunity The US market potential for BXT-25 is estimated at $10 billion Cerebrovascular Accidents Traumatic Brain Injury (TBI) Anti-Necrosis » Anemia Treatment » Cancer » Human Organ Transplants BioXyTrai Lis PRODUCT DESCRIPTION OBJECTIVE TIMELINE BXT-251 Univer
Slide 21: Inadequate Treatment Options
Inadequate Treatment Options STEP 1— Determination of Ischemic or Hemorrhagic Stroke (Imaging) STEP 2 — Tissue Plasminogen Activator (tPA) for Ischemic Stroke or Surgery — [Clipping Artery, Insert Coiling to Force Clotting] for Hemorrhagic NO TREATMENT CAN BE GIVEN UNTIL DIAGNOSIS IS COMPLETED 13% o
Slide 22: Ideal Stroke Treatment
Ideal Stroke Treatment EVERY MINUTE COUNTS! ULTIMATE TREATMENT CHARACTERISTICS Restore Oxygen to the Brain Efficacy for Ischemic and Hemorrhagic Strokes No Side Effects Easy to Administer Treatment for First Responders THE CONCEPTBEHIND §=Bio.Xy Trans EXTEND THE “GOLDEN HOUR” TO TREAT STROKE VICTIMS
Slide 23: The Brain Stroke Epidemic
Bio.XyTran.. The Brain Stroke Epidemic A Challenge to Worldwide Healthcare, a $184 Billion Medical Indication Costs Tele nere Ae fon HV | HNL il (LI ri REGION estimated $74 World 17.0 estimated $184
Slide 24: BXT-25 Is Designed with Characteristics for Stroke Treatment
BXT-25 Is Designed with Characteristics for Stroke Treatment - Restores oxygen to the brain - Creates efficacy for both ischemic and hemorrhagic strokes - Results in no known side effects - Delivers viable treatment for first responders - Enables immediate treatment prior to diagnostic imaging Bio X
Slide 25: Hyperbaric Chamber Obsolescence
Hyperbaric Chamber Obsolescence Hyperbaric Chamber Indications -Decompression Sickness -Wound Healing -Burn victims -Infections -Stroke -Lyme Disease -Parkinson’s Disease -Alzheimers Disease -Carbon Monoxide Poisoning -Cancer Chemotherapy -Radiation injury BioXyTran.. ~ s Advantages — Easier adminis
Slide 26: Licensing Zone
Licensing Zone es * Complete safety studies in healthy human patients ¢ Target coma patients for initial studies ¢ Create credibility of third vital sign with influencers ¢ Raise $10 million in equity related financing ¢ Identify and approach key target licensees ¢ Attract research coverage and inst
Slide 27: Bioxytran Has a Clear Plan to Achieve FDA Approval
BioXyTran.. Bioxytran Has a Clear Plan to Achieve FDA Approval 1. CMC Production 5. CMC Production 6. Phase I(a) z, Phase Ill + Manufacture (USA) + Manufacture (USA) + Healthy Volunteers (40) Stroke Patients (300) * Human Heme * Human Heme * Dose Limiting Toxicity * National Institute of * GLP * GMP
Slide 28: Leadership
Leadership David Platt, Ph.D/CEO Ph.D in Chemical Engineering, Hebrew University of Jerusalem; Weizmann Institute; Founder of five public Bio-Tech companies over a 25 year period with a combined market capitalization of more than $1.5 billion Elena Chekhova, Ph.D/Chief Scientist Ph.D in Process Syst
Slide 29: Use of Proceeds
Bio.XyTran.. Use of Proceeds Event FUNDING TIMELINE Manufacturing CMC $400K 4mo. Preclinical (2 Species — Rats & Dogs) $600K 3mo. Phase 1 (BXT-25) $400K 2mo. 30 Phase 2 $2.0 mil 6 mo. 60 SG&A Expense $3.4 mil MDxX Licensing Deal $3.2 mil Total $10 Million
Slide 30: Effective S-1 registration
BioXyTran.. Effective S-1 ™ Proposed Maximum Amountto be Offering Title of Each Class of Security Being Registered Registered Price Common Stock, $0.001 par value 10,000,000 $ 1.00 Common Stock, $0.001 par value (3) 3,285,821 Common Stock Underlying Warrants (4) 208,333 Total 13,494,154 (Estimated s
Slide 31: BioXyTran, Inc.
BioXyTran, Inc. 233 Needham St., Suite 300 Newton MA, 02464 (617)-454-1199 www.bioxytraninc.com David Platt, CEO david.platt @bioxytraninc.com (617)-510-2539